It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
AI Meets Expertise: A hybrid Workflow For Modern Target ID | QIAGEN & Sygnature
In drug discovery, generating targets is no longer the challenge.
The real question is how to identify the few worth investing months of research and significant resources to pursue.
Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Channelrhodopsin: A protein tool being used to help our brain understand itself
We in the Protein Science & Structural Biology department are passionate about proteins, and membrane proteins in particular. So, imagine our joy when we saw that a membrane protein was at the center of this year’s Nobel Prize for Medicine.
Join us in an exploration of this intriguing molecule and how it came to be involved in helping us try to understand how our brain works.
“The human brain is the only thing on the planet that is trying to understand itself”
from a talk on the NMDA receptor & memory at Zeneca Pharmaceuticals 1992. R. Mott
“Dear Hilde, if the human brain was simple enough for us to understand, we would still be so stupid that we couldn’t understand it”
from Sophie’s World by Jostein Gaarder
Introduction
Few proteins have had as profound an impact on modern biology as channelrhodopsin. What began as an investigation into how microscopic green algae sense and respond to light ultimately led to one of the most transformative technologies in neuroscience: optogenetics.
Today, channelrhodopsins allow researchers to control the activity of specific neurons with millisecond precision using light, enabling experiments that were previously impossible. The impact of this technology was recognized with the 2026 Nobel Prize for Medicine.
From a protein biochemistry perspective, channelrhodopsins are fascinating molecules. They combine a light-sensing chromophore with an ion channel in a single protein, directly converting photons into electrical signals without requiring intermediary signaling pathways. This elegant molecular design explains both their biological function in algae and their extraordinary utility as research tools to drive our understanding of how the human brain actually works.
From Algal Photoreceptor to the Engine of Optogenetics
It all began with the unicellular green alga Chlamydomonas reinhardtii, a photosynthetic microorganism that can actively swim toward or away from light sources, a behavior known as phototaxis.
Researchers in the 1970s and 1980s sought to understand the molecular basis of this light-guided movement. Physiological studies demonstrated that illumination of the algal eyespot triggered rapid changes in membrane potential and ion fluxes, suggesting the presence of a specialized photoreceptor linked to ion transport.
A major clue emerged from studies of microbial rhodopsins. Bacteriorhodopsin and halorhodopsin had already been identified in archaea as retinal-containing membrane proteins capable of light-driven ion transport. Scientists suspected that a related class of proteins might exist in algae.
The breakthrough came in the early 2000s when genomic and electrophysiological investigations identified two novel photoreceptor proteins in C. reinhardtii:
Channelrhodopsin-1 (ChR1)
Channelrhodopsin-2 (ChR2)
In 2002, Nagel and colleagues demonstrated that Channelrhodopsin-1 functions as a light-gated ion channel. Shortly thereafter, Channelrhodopsin-2 was shown to mediate rapid light-induced cation conductance. These findings revealed an entirely new type of photoreceptor: a single-component protein that directly converts light into ion flux.
Unlike vertebrate visual rhodopsins, which activate G-protein signaling cascades, channelrhodopsins operate as much simpler, self-contained molecular machines.
The full story of these initial observations, the subsequent studies into the underlying mechanism via the ChR1 and 2 proteins and how the proteins ultimately ended up as the tools powering the engine of Optogenetics is beautifully described in this Nobel Prize announcement article.
It is a wonderful scientific journey, beginning with Hegemann’s curiosity to understand how algae sense light, followed by Nagel’s work identifying the proteins underlying these responses and uncovering the mechanism. The final “creative” moment, demonstrating the power of cross functional collaboration, came when Desseroth and colleagues recognized that channelrhodopsins could be used to trigger electrical impulses in nerve cells. The subsequent development of methods to make this work in living animals laid the foundations for optogenetics.
Figure 1: The X-ray crystallography structure of C. reinhardtii channelrhodopsin (PDB : 3UG9)
Protein Structure and Biochemistry of Channelrhodopsins
A Retinal-Binding Membrane Protein
Channelrhodopsins belong to the microbial rhodopsin superfamily. Like other rhodopsins, they contain:
Seven transmembrane α-helices
A covalently bound retinal chromophore, derived from vitamin A that serves as the light-absorbing component of the protein.
Conserved amino acids that coordinate retinal and govern photochemistry
Significant progress in understanding channelrhodopsin function came from structural biology, with the first high-resolution crystal structure of a channelrhodopsin being reported in 2012.
Beyond simply revealing the architecture of the protein, these studies helped explain how absorption of light by retinal is coupled to opening of the ion-conducting pore. As an integral membrane protein, however, channelrhodopsin presented many of the challenges familiar to structural biologists, including recombinant expression, extraction from lipid membranes and maintenance of stability outside its native environment.
To solve this initial structure Kato et al., (2012) screened a number of engineered channelrhodopsin constructs from C. reinhardtii and other organisms. The successful construct was a chimeric version of C. reinhardtii channelrhodopsin that they named C1C2, which consisted of ChR1 without the C terminus, with the last two TM regions exchanged for those from ChR2. At the C-terminus a TEV-eGFP-8His tag was added. The eGFP for use in the initial construct screening in HEK293 cells using fSEC and the His tag to aid purification. To support the crystallization studies this construct was expressed in baculovirus infected Sf+ insect cells and purified following solubilization of the membrane fraction.
This and subsequent structural studies provided direct insights into:
Retinal positioning: Which is attached via a protonated Schiff base linkage to a lysine residue within the protein.
Pore architecture: With multiple constriction sites identified within the pore that regulate ion permeation.
Ion-conducting pathways: Unlike highly selective ion channels, Channelrhodopsin-2 functions as a relatively non-selective cation channel that displays
Fast activation
Moderate conductance
Broad cation permeability
Gating mechanisms: Gating involves coordinated movement of residues within the transmembrane bundle, creating transient aqueous pathways through the protein.
This combination of features makes channelrhodopsin particularly effective at depolarizing cells. In native algae, this depolarization triggers those behavioral responses to light that Hegemann and others had observed.
The Photocycle
The central biochemical event underlying channelrhodopsin function is retinal photoisomerization.
In the dark state:
Retinal exists predominantly in the all-trans configuration.
The ion channel remains closed.
Upon absorption of a photon:
Retinal rapidly isomerizes.
Structural rearrangements propagate through the transmembrane helices.
The channel pore opens.
This process occurs on the microsecond timescale, and the resulting open state permits the passage of cations including: H⁺, Na⁺, K⁺ and Ca²⁺. The protein subsequently progresses through a series of photointermediates before returning to its original dark state.
The complete photocycle occurs within milliseconds, allowing repeated stimulation at high frequencies. And it is this rapid response that was one of the key factors that meant that channelrhodopsins were ideal to be developed as tools for use in the new field of optogenetics.
Subsequent cryo-electron microscopy and crystallographic studies on the C. reinhardtii and other related channelrhodopsins have revealed how subtle amino acid substitutions can dramatically alter:
Absorption wavelength
Kinetic behavior
Ion selectivity
Light sensitivity
This structural understanding laid the foundation for protein engineering efforts that transformed channelrhodopsins into versatile optogenetic tools. (See later for more detail)
Figure 2: The cryo-EM structure of Kalium channelrhodopsin 1 from Hyphochytrium catenoides, Dark State (PDB : 9CDC)
The Birth of Optogenetics
Although the algal proteins themselves were fascinating, their greatest impact came from an unexpected application, described more fully in the Nobel Prize announcement article.
In 2005, Karl Deisseroth, Edward Boyden and colleagues demonstrated that expression of Channelrhodopsin-2 in mammalian neurons allowed neuronal firing to be controlled by pulses of blue light.
This was a revolutionary concept.
Rather than using electrodes to stimulate neurons:
Introduce the channelrhodopsin gene.
Express the protein in selected cells.
Illuminate with light.
Trigger action potentials with millisecond precision.
The simplicity of the system was unprecedented because channelrhodopsin required only:
The protein itself
Endogenous retinal already present in mammalian tissues
No additional signaling components were necessary.
The technology quickly became known as optogenetics, combining optical control with genetic targeting.
The concept was remarkably simple, but its impact was transformative. For the first time, researchers could selectively activate specific neurons within a living animal and directly observe the effects on behavior. Neuroscience could move beyond observing correlations and begin testing cause and effect.
Why Channelrhodopsin Was Ideal for Optogenetics
From a protein science perspective, channelrhodopsin is particularly elegant. Unlike many biological signaling systems that require multiple proteins, channelrhodopsin combines light sensing and ion channel activity within a single seven-transmembrane protein, making it both mechanistically fascinating and highly amenable to experimental study.
Several biochemical properties made channelrhodopsin uniquely suitable.
Single-Component Functionality
Many signalling proteins require complex accessory pathways.
Channelrhodopsin functions independently, making heterologous expression straightforward.
Fast Kinetics
Neurons communicate on the millisecond timescale.
Channelrhodopsin activation and deactivation kinetics are similarly rapid, enabling faithful control of neural firing patterns.
Direct Electrical Control
The protein directly conducts ions rather than activating secondary messengers.
This creates predictable and reproducible membrane depolarization.
Genetic Targetability
The channelrhodopsin gene can be placed under cell-type-specific promoters.
This enables selective control of defined neuronal populations.
Engineering Better Channelrhodopsins
The original Channelrhodopsin-2 molecule was remarkably effective but based on the cryo-EM and X-ray structure data, researchers soon began engineering variants with improved properties, generating an extensive toolbox tailored for specific experimental needs to progress the optogenetics field.
Examples include:
H134R: An early mutation that increased photocurrents and improved expression.
ChETA: Variants with faster closing kinetics that enable high-frequency neuronal stimulation.
C1V1: Red-shifted channelrhodopsins activated by longer wavelengths of light that penetrate tissue more effectively.
Chrimson: A red-light activated channelrhodopsin that supports deeper tissue stimulation.
ChRmine: An ultra-sensitive channelrhodopsin with exceptionally large photocurrents and improved performance for in vivo applications.
Other Applications Beyond Optogenetics
The use of channelrhodopsin tools has branched out to other areas of research. Applications include:
Mapping neural circuits
Studying memory formation
Investigating psychiatric disorders
Cardiac electrophysiology
Pancreatic β-cell regulation
Skeletal muscle control
Developmental biology
Synthetic biology
Researchers are also exploring therapeutic applications for:
Vision restoration: Several clinical programs have investigated channelrhodopsin-based approaches for restoring visual responses in patients suffering from photoreceptor loss.
Epilepsy
Parkinson’s disease
Retinal degeneration
CONCLUSION
Channelrhodopsin represents one of the most important discoveries at the intersection of protein biochemistry, structural biology and neuroscience. Originally evolved to help green algae navigate their light environment, this retinal-binding membrane protein revealed a fundamentally new mechanism for converting photons directly into ionic currents.
Its elegant architecture, consisting of a seven-transmembrane rhodopsin scaffold fused to a light-gated ion channel, provided a ready-made molecular switch perfectly suited for biological engineering. The subsequent adoption of Channelrhodopsin-2 as the foundation of optogenetics revolutionized the study of neural circuits and opened entirely new avenues for understanding physiology and disease.
In many ways, channelrhodopsin embodies one of the most powerful ideas in science: that curiosity driven investigations can deliver transformative technologies. A protein that evolved to help a single-celled alga navigate its environment now allows researchers to probe the workings of the most complex biological structure known, the human brain.
Foster, K. W., & Smyth, R. D. (1980). Light antennas in phototactic algae. Microbiological Reviews, 44(4), 572-630. DOI: Not assigned.
Harz, H., & Hegemann, P. (1991). Rhodopsin-regulated behavioural responses in the green alga Chlamydomonas. Nature, 351, 489-491. DOI: 10.1038/351489a0
Sineshchekov, O. A., Jung, K. H., & Spudich, J. L. (2002). Two rhodopsins mediate phototaxis to low and high light intensities in Chlamydomonas reinhardtii. Proceedings of the National Academy of Sciences USA, 99(13), 8689-8694. DOI: 10.1073/pnas.122243399
Nagel, G., Ollig, D., Fuhrmann, M., Kateriya, S., Musti, A. M., Bamberg, E., & Hegemann, P. (2002). Channelrhodopsin-1: A light-gated proton channel in green algae. Science, 296(5577), 2395-2398. DOI: 10.1126/science.1072068
Nagel, G., Szellas, T., Huhn, W., Kateriya, S., Adeishvili, N., Berthold, P., Ollig, D., Hegemann, P., & Bamberg, E. (2003). Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proceedings of the National Academy of Sciences USA, 100(24), 13940-13945. DOI: 10.1073/pnas.1936192100
Hegemann, P. (2008). Algal sensory photoreceptors. Annual Review of Plant Biology, 59, 167-189. DOI: 10.1146/annurev.arplant.59.032607.092847
Boyden, E. S., Zhang, F., Bamberg, E., Nagel, G., & Deisseroth, K. (2005). Millisecond-timescale, genetically targeted optical control of neural activity. Nature Neuroscience, 8(9), 1263-1268. DOI: 10.1038/nn1525
Deisseroth, K. (2011). Optogenetics. Nature Methods, 8(1), 26-29. DOI: 10.1038/nmeth.f.324
Berndt, A., Yizhar, O., Gunaydin, L. A., Hegemann, P., & Deisseroth, K. (2009). Bi-stable neural state switches. Nature Neuroscience, 12(2), 229-234. DOI: 10.1038/nn.2247
Kato, H. E., Zhang, F., Yizhar, O., Ramakrishnan, C., Nishizawa, T., Hirata, K., et al. (2012). Crystal structure of the channelrhodopsin light-gated cation channel. Nature, 482, 369-374. DOI: 10.1038/nature10870
Wietek, J., & Prigge, M. (2016). Optogenetic tools derived from microbial rhodopsins. Biological Chemistry, 397(2), 139-149. DOI: 10.1515/hsz-2015-0269
Klapoetke, N. C., Murata, Y., Kim, S. S., Pulver, S. R., Birdsey-Benson, A., Cho, Y. K., et al. (2014). Independent optical excitation of distinct neural populations. Nature Methods, 11, 338-346. DOI: 10.1038/nmeth.2836
Marshel, J. H., Kim, Y. S., Machado, T. A., Quirin, S., Benson, B., Kadmon, J., et al. (2019). Cortical layer-specific critical dynamics triggering perception. Science, 365(6453), eaaw5202. DOI: 10.1126/science.aaw5202
Bedbrook, C. N., Yang, K. K., Robinson, J. E., Mackey, E. D., Gradinaru, V., & Arnold, F. H. (2019). Machine learning-guided channelrhodopsin engineering enables minimally invasive optogenetics. Nature Methods, 16, 1176-1184. DOI: 10.1038/s41592-019-0583-8
Marshel, J. H., Callaway, E. M., Raimondo, J. V., et al. (2022). ChRmine enables ultrapotent optogenetic manipulation. Nature, 606, 411-420. DOI: 10.1038/s41586-022-2478-5
Deisseroth, K. (2015). Optogenetics: 10 years of microbial opsins in neuroscience. Nature Neuroscience, 18(9), 1213-1225. DOI: 10.1038/nn.4091
Fenno, L., Yizhar, O., & Deisseroth, K. (2011). The development and application of optogenetics. Annual Review of Neuroscience, 34, 389-412. DOI: 10.1146/annurev-neuro-061010-113817
Govorunova, E. G., Sineshchekov, O. A., Janz, R., Liu, X., & Spudich, J. L. (2015). Natural light-gated anion channels: A family of microbial rhodopsins for advanced optogenetics. Science, 349(6248), 647-650. DOI: 10.1126/science.aaa7484
Ernst, O. P., Lodowski, D. T., Elstner, M., Hegemann, P., Brown, L. S., & Kandori, H. (2014). Microbial and animal rhodopsins: Structures, functions, and molecular mechanisms. Chemical Reviews, 114(1), 126-163. DOI: 10.1021/cr4003769